Frevecitinib

N/A

Report date: 2026/04/16 20:00:17
NME

Base Information

Drug NameFrevecitinib
Drug Alias NameVR-588KN-002KN-002 (Kinaset Therapeutics/Vectura)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK2 inhibitorsTyrosine-protein kinase JAK3 inhibitorsTyrosine-protein kinase JAK1 inhibitors +[4] 
TargetsTyrosine-protein kinase JAK2Transient receptor potential cation channel subfamily V member 1Tyrosine-protein kinase JAK3 +[4] 
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesVectura Ltd
China Registration ClassN/A

Develop Information

Active CompaniesKinaset Therapeutics Inc
Inactive CompaniesVectura Ltd
Active IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A